TrialHuman vaccines & immunotherapeutics2014

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination.

Paulo S Naud et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.